Jazz Pharmaceuticals plc Receivables

Jazz Pharmaceuticals plc (JAZZ) currently reports a receivables of $840M as of March 2026. That compares with $650M in the prior-year period — up 28.1% year over year. Use the charts on this page to explore Jazz Pharmaceuticals plc's receivables history and peer comparisons.

Jazz Pharmaceuticals plc's receivables increased from $650M to $840M — a 28.1% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Jazz Pharmaceuticals plc reported $840M in receivables as of March 2026. That compares with $650M in the prior-year period — up 28.1% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $840M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Jazz Pharmaceuticals plc, and consider following JAZZ for alerts when major investors trade the stock.

Jazz Pharmaceuticals plc is classified in the Healthcare sector. On receivables, it currently shows $840M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing JAZZ with unrelated industries.